T47D-182R2 Cell Line

Catalogue number: 151890
Sub-type: Continuous
Images:

Contributor

Inventor: Anne Lykkesfeldt
Institute: Danish Cancer Society
Images:

Tool details

***FOR RESEARCH USE ONLY**

Name: T47D-182R2 Cell Line

Alternate name:

Class:
Conjugate:
Description: The T47D-182R2 Cell Line is a breast cancer cell line resistant to fulvestrant. Treatment with the steroidal antiestrogen fulvestrant has proven effective upon progression on tamoxifen therapy and is now approved for second-line treatment after tamoxifen or aromatase inhibitors. As for tamoxifen treatment of advanced breast cancer, resistance will inevitably occur also for fulvestrant. Clarification of the molecular changes associated with the resistant growth is needed to find targeted treatments to resistant tumour cells and treatments that can inhibit or delay the emergence of resistance.
Purpose:
Parental cell: T47D
Organism: Human
Tissue: Breast
Model: Tumour line
Gender:
Isotype:
Reactivity:
Selectivity:
Host:
Immunogen:
Immunogen UNIPROT ID:
Sequence:
Growth properties:
Production details:

Human breast cancer cell line derived from T47D/S5 by long term treatment with 100 nM fulvestrant. Grow with 5% feal calf serum and 100 nM fulvestrant. Estrogen and progesterone receptor negative. Passage 165 (AL3370, AL3384)
Formulation:
Recommended controls:
Bacterial resistance:
Selectable markers:
Additional notes:

Target details

Target: Oestrogen receptor

Target alternate names:

Target background:

Molecular weight:

Ic50:

Applications

Application:
Application notes: Estrogen and progesterone receptor negative.

Handling

Format: Frozen
Concentration:
Passage number: Passage 165 (AL3370, AL3384)
Growth medium: Phenol red free RPMI 1640 + 5% FCS + glutamax + 8????g Insulin/ml + 100 nM fulvestrant. Grow with 5% feal calf serum and 100 nM fulvestrant.
Temperature:
Atmosphere:
Volume:
Storage medium:
Storage buffer:
Storage conditions:
Shipping conditions: Dry ice

Related tools

Related tools: T47D/S2 Cell Line

References

References: Zhao et al. 2006. Cancer Res. 66(10):5354-62. PMID: 16707462. ; Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. ; Leahy et al. 2004. Bioorg Med Chem Lett. 14(24):6083-7. PMID: 15546735. ; Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries.